Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

284858

Sigma-Aldrich

(−)-Norgestrel

98%

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
797-63-7
Molecular Weight:
312.45
EC Number:
212-349-8
MDL number:
MFCD00199013
UNSPSC Code:
12352115
PubChem Substance ID:
24857181

Assay

98%

optical activity

[α]20/D −32°, c = 1 in chloroform

mp

239-241 °C (lit.)

SMILES string

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(CC)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

Gene Information

human ... PGR(5241)
rat ... Ar(24208)

Application

Product No.
Description
Pricing

replaced by

Product No.
Description
Pricing

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H351,H360D,H362

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Satu Heliövaara-Peippo et al.
American journal of obstetrics and gynecology, 209(6), 535-535 (2013-09-04)
Menorrhagia is a common problem impairing the quality of life (QOL) of many women. Both levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy are effective treatment modalities but no long-term comparative studies of QOL and costs exist. The objective of this study
Alice W Y Wong et al.
Obstetrics and gynecology, 121(5), 943-950 (2013-05-03)
To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen. This was a randomized contro-lled trial of 129 Chinese women who attended a university hospital in Hong
T E Roberts et al.
BMJ (Clinical research ed.), 342, d2202-d2202 (2011-04-28)
To undertake a cost effectiveness analysis comparing first and second generation endometrial ablative techniques, hysterectomy, and the levonorgestrel releasing intrauterine system (Mirena) for treating heavy menstrual bleeding. Model based economic evaluation with data from an individual patient data meta-analysis supplemented
Ian S Fraser
Contraception, 87(3), 273-279 (2012-10-09)
It has been recognized for well over half a century that hormonal preparations designed as contraceptives are also capable of offering health benefits through the treatment and prevention of benign gynecological disease and even some systemic conditions. Increasing attention is
Elizabeth A McCarthy et al.
Contraception, 86(5), 587-590 (2012-04-14)
Correctly placed levonorgestrel-releasing intrauterine systems (LNG-IUSs) are rarely associated with intrauterine pregnancy when pregnancy occurs. LNG-IUS retrieval, termination of pregnancy and conservative management if retracted strings prevent ready removal are the usual clinical options given to women. The conservative course
View All Related Papers

Chromatograms

application for HPLC

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service